布地奈德对大鼠变应性鼻炎最轻持续炎症反应模型IL-12表达的影响

李仲; 耿曼英

doi:10.13201/j.issn.1001-1781.2015.03.022

布地奈德对大鼠变应性鼻炎最轻持续炎症反应模型IL-12表达的影响

李仲,
耿曼英^,

- 郑州大学第二附属医院耳鼻咽喉头颈外科(郑州, 450000)

详细信息

通讯作者: 耿曼英,E-mail:manying66@126.com

中图分类号: R765.21

收稿日期: 2014-09-27

Effect of budesonide on the expression of IL-12 in animal model of minimal persistent inflammation of allergic rhinitis in rats

LI Zhong,
GENG Manying^,

- Department of Otolaryngology Head and Neck Surgery, Second Affiliated Hospital of Zhengzhou University, Zhengzhou, 450000, China

More Information

Corresponding author: GENG Manying, E-mail: manying66@126.com

Received Date: 27 September 2014

摘要

摘要: 目的:研究布地奈德对大鼠变应性鼻炎(AR)最轻持续炎症反应(MPI)模型的影响并观察IL-12的表达变化。方法:60只健康SD大鼠随机分为A、B、C、D共4组,每组15只。A组为阳性对照组即AR组,B组为实验组即MPI给药组,C组为阴性对照组即MPI不给药组,D组为空白对照组。首先以含卵清蛋白(OVA)和氢氧化铝凝胶的生理盐水混合液对A、B、C 3组行基础致敏和强化致敏,再分别用1%和0.01%的OVA溶液或生理盐水长期鼻腔激发,D组始终以生理盐水进行致敏和激发。第36天起每次激发前30 min B组给予布地奈德喷鼻,其余各组给予生理盐水代替。观察豚鼠鼻腔激发后症状(喷嚏)变化并检测鼻黏膜中嗜酸粒细胞(EOS)浸润程度、上皮细胞内细胞间黏附分子1(ICAM-1)及IL-12的表达情况。结果:B组在以1% OVA溶液激发时,喷嚏平均次数明显多于D组(P<0.05),而与A、C组相比差异均无统计学意义(P>0.05);改用0.01% OVA溶液鼻腔激发并给药后,AR症状基本消失,与D组相比差异无统计学意义(P>0.05),鼻黏膜内仍有少量EOS浸润,并可见上皮细胞ICAM-1轻度表达,但与D组相比差异无统计学意义(P>0.05), B组IL-12阳性表达明显,与D组相比差异无统计学意义。结论:布地奈德可显著抑制AR模型迟发相炎症反应,提高大鼠AR MPI模型IL-12的表达。
- 鼻炎 /
- 变应性 /
- 细胞间黏附分子1 /
- 白细胞介素12 /
- 布地奈德
Abstract: Objective: To investigate the influence of budesonide on animal model of minimal persistent inflammation (MPI) of allergic rhinitis in rats and to investigate the changes of interleukin-12 (IL-12) in nasal mucosa.Method: Sixty Sprague-Dawley (SD) rats were randomly divided into four groups:group A (allergic rhinitis group),B (experimental group),C(MPI model group) and D (bland group) respectively,with fifteen animals in each group. Rats from group A,B and C were sensitized intraperitoneally by injection of suspension of ovalbumin (OVA) and aluminum hydroxide in 0.9% physiological saline. Then, repeated local booster sensitization with different concentration of OVA suspension (1% and 0.01%) or physiological saline into the nasal cavity of those rats were performed.For group D,physiological saline was used only. From 36th day, group B were given budesonide treatment for three weeks. A,C and D group were given normal saline nasal spray. Symptoms (sneezing) of rats after antigen challenge were observed and the infiltration of eosinophils (EOS) together with the expression of intercellular adhesion molecule 1 (ICAM-1) and IL-12 in the nasal epithelial cells were also examined.Result: When challenged with 1% OVA,the sneezing number of rats in group B was increased markedly than that in group D (P<0.05). However,there was no difference between group B,A and C (P>0.05). When challenged with 0.01% OVA and given budesonide ,the symptom of sneezing almost disappeared in group B just like that in group D and there was no difference between the two groups (P>0.05). Besides,there was still more EOS infiltrated in the nasal mucosa of rats in group C than that in group D(P<0.05). There was no expression of ICAM-1 in nasal epithelium of rats in group D,nevertheless,ICAM-1 was found mildly expressed in group C. IL-12 expression was significantly increased compared with group A and group C, and was no significantly difference compared with bland group(P>0.05).Conclusion: Budesonide significantly inhibited the late reaction of animal model of minimal persistent inflammation (MPI) of allergic rhinitis in rats and increase the expression of IL-12 in MPI model.
- rhinitis /
- allergic /
- intercellular adhesion molecule-1 /
- interleukin-12 /
- budesonide

HTML全文

参考文献(15)

[1]	BOUSQUET J,KHALTAEV N,CRUZ A A,et al.Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2) LEN and AllerGen)[J]. Allergy,2008,63:8-160.
[2]	RIVERA J,GILFILLAN A M.Molecular regulation of mast cell activation[J].J Allergy Clin Immunol,2006,117:1214-1225.
[3]	雷菲,朱冬冬,孔红,等.豚鼠实验性变应性鼻炎最轻持续炎症反应模型的建立[J].中华耳鼻咽喉头颈外科杂志,2008,43(6):443-446.
[4]	余文煜,董震.实验性变应性鼻炎鼻黏膜组织重塑的特点[J].中华耳鼻咽喉头颈外科杂志,2006,41(1):48-53.
[5]	OHASHI Y, NAKAI Y, TANAKA A, et al. Clinical role of soluble adhesion molecules during immunotherapy for perennial allergic rhinitis[J].Arch Otolaryngol Head Neck Surg, 1998, 124:41-45.
[6]	MILANESE M,RICCAV,CANONLCA G W,et al. Eosinophils,specific hyperreactivity and occurrence of late phase reaction in allergle rhinitis[J].Eur Ann Allergy Clin Immunol,2005,37:7-10.
[7]	龚非力.医学免疫学[M].北京:科学出版社,2003:156-156.
[8]	MARSHALL J D,SECRIST H,DEKRUYFF B H.IL-12 inhibits the production of IL-4 and IL-10 in allergen-specific human CD4+T lymphocytes[J].J Immunol,1995,155:111-117.
[9]	邓秋,周芸,杨军,等.变应性鼻炎动物模型白细胞介素12与嗜酸性粒细胞的变化[J].中国耳鼻咽喉头颈外科,2006,13(2):113-116.
[10]	周兵,韩德民,王彤,等.内细胞介索12基因治疗小鼠变应性鼻炎的实验研究[J].中华耳鼻咽喉头颈外科杂志,2005,40(6):444-448.
[11]	LIU M,ZHENG S,WANG X,et al.Regulatory roles of IL-12.IL-4 and IFN-gamma on IgE synthesis in atopic patients[J].Chin Med J(Engl),1999,112:550-553.
[12]	张秋贵,李薇,郑东淑,等.细胞间黏附分子-1和白细胞介素-6在变应性鼻炎鼻和支气管黏膜中的表达及意义[J].临床耳鼻咽喉科杂志,2004,18(5):261-264.
[13]	NIELSEN L P, MYGIND N,DAHL R.Intranasal corticosteroids for allergic rhinitis superior relief[J].Drugs,2001,61:1563-1579.
[14]	FOKKENS W J,CSERHATI E,DOS SANTOS J M,et al.Budesonide aqueous nasal spray is an efective treatment in children with perennial allergic rhinitis,with an onset of action within 12 hours[J].Ann Allergy Asthma Inununol,2002,89:279-284.
[15]	DALEY-YATES P T,BAKER R C.Systemic bioava-ilability of fluticasone propionate administered as nasal drops and aqueous nasal spray formulations[J].Br J Clin Pharmacol,2001,51:103-108.